In silico prevalidation is required in early phase of biomarkers development study [21, 90], to optimize potential biomarkers prior to large scale studies. The cost implication and infrastructure needed for large scale validation of omics based biomarkers can be prohibitive , hence collaborative efforts such as the EDRN are necessary to achieve this goal . In addition, standard validation procedures often require validated surrogate prognostic biomarkers that have been tested in multiple phase III trials . Due to prohibitive costs, only important proteins or antibodies from the discovery phase would typically be validated . Proteogenomic integration is thus an important multipronged approach to identify viable diagnostic and treatment signatures for PCa. For example, androgen receptors (AR) and EGFR has been identified as correlating with PCa progression using gene expression data integrated with protein interaction networks . In line with an integrated proteogenomic approach, other emerging liquid biopsy biomarkers such as long non-coding RNA and exosomes holds future prospects for PCa . Sixteen putative proteomics biomarkers of PCa validated on a well annotated tissue microarray (TMA) containing ca. 2500 PCa samples has been used to establish a prediction nomogram for PCa . Several genomic classifiers have also emerged for clinical metastasis and biochemical recurrence, as well as for patient stratification . Hitherto, most discovered biomarkers have focused on diagnostic rather than prognostic and predictive potentials . As emphasized earlier, there is an urgent need for larger biorepository establishment to facilitate disease biomarker discovery and validation . Emerging biomarkers such as circulating tumour cells (CTC) in blood may enable the evaluation of disease prognosis and survival . Advances in PCa biomarker development has resulted in the clinical utility of laboratory tests such as Prolaris score, Oncotype Dx, Confirm MDx, Prostarix and 4K score . These tests have helped to improve diagnosis of PCa and decipher the level of evidence (LoE) assigned for biomarker validation . Urine and blood sample testing for biomarkers is a reasonable approach with high prospect for mass screening of populations for disease , particularly in African populations that are at greater risk of developing aggressive PCa.